PMC:7696151 / 85881-86052 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"2537","span":{"begin":60,"end":68},"obj":"Species"},{"id":"2552","span":{"begin":124,"end":127},"obj":"Chemical"},{"id":"2573","span":{"begin":74,"end":81},"obj":"Disease"}],"attributes":[{"id":"A2537","pred":"tao:has_database_id","subj":"2537","obj":"Tax:9606"},{"id":"A2552","pred":"tao:has_database_id","subj":"2552","obj":"MESH:D006886"},{"id":"A2573","pred":"tao:has_database_id","subj":"2573","obj":"MESH:D009101"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"According to the results of Rangwala, a phase I trial on 25 patients with myeloma demonstrated that the recommended dose of HCQ for a phase II trial is 600 mg twice a day."}

{"project":"LitCovid-sentences","denotations":[{"id":"T546","span":{"begin":0,"end":171},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"According to the results of Rangwala, a phase I trial on 25 patients with myeloma demonstrated that the recommended dose of HCQ for a phase II trial is 600 mg twice a day."}